408308-07-6

Upstream product

• 623-43-8 methyl crotonate 
• 135-02-4 ortho-anisaldehyde 
• 643746-88-7 5-(2-methoxyphenyl)pentanoic acid ethyl ester 
• 1019654-18-2 (2E,4E)-ethyl 5-(2-methoxyphenyl)penta-2,4-dienoate 
• 408308-34-9 ethyl 5-(2-methoxyphenyl)pentadienoate 
• 70311-27-2 2-methoxybenzenepropanoic acid ethyl ester 
• 33877-05-3 ethyl 3-(2-methoxyphenyl)acrylate 
• 33538-83-9 3-(2-methoxyphenyl)propanal 
• 10493-37-5 3-(2-methoxyphenyl)propan-1-ol 
• 612-16-8 (2-methoxyphenyl)methanol 
• 264598-04-1 <3-(2-Methoxy-phenyl)-allyliden>-malonsaeure 

Downstream Products

• 643746-89-8 tert-butyl 4-(2,4-difluoro-5-{[5-(2-methoxyphenyl)pentanoyl]amino}phenyl)-1-piperidinecarboxylate 
• 643746-93-4 tert-butyl 4-(4-fluoro-3-{[5-(2-methoxyphenyl)pentanoyl]amino}phenyl)-1-piperidinecarboxylate 
• 1452406-11-9 1,1,1-trifluoro-6-(2-methoxyphenyl)hexan-2-one 
• 1452406-20-0 1,1,1,2,2-pentafluoro-7-(2-methoxyphenyl)heptan-3-one 

Relevant academic research and scientific papers

New potent and selective polyfluoroalkyl ketone inhibitors of GVIA calcium-independent phospholipase A2

Group VIA calcium-independent phospholipase A2 (GVIA iPLA 2) has recently emerged as an important pharmaceutical target. Selective and potent GVIA iPLA2 inhibitors can be used to study its role in various neurological diso

Discovery of synthetic methoxy-substituted 4-phenylbutyric acid derivatives as chemical chaperones

In this study, we evaluated the chemical chaperone activity of synthetic 4-phenylbutyric acid (4-PBA) derivatives. These derivatives have a methoxy group at the benzene ring and/or longer or shorter fatty acid portions. Several 4-PBA derivatives demonstrated higher antiaggregation activity than 4-PBA. Moreover, 4-(4-methoxyphenyl)butanoic acid (7b) showed protective effects against endoplasmic reticulum stress-induced neuronal cell death.

PHENYLALKYLCARBOXYLIC ACID DELIVERY AGENTS

The present invention provides phenylalkylcarboxylic acid compounds and compositions containing such compounds which facilitate the delivery of biologically active agents.

SECONDARY AMINO ANILINIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compounds of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.